eloralintide vs retatrutide Novo Nordisk Eli Lilly: Who's Winning the Obesity Drug Race? Experimental Obesity Drug Eloralintide Helped

Description

Meals and snacks with GLP-1 Friendly labels on the packaging are becoming more common in U.S

Retatrutide offers powerful benefits for weight loss, metabolic health, and liver function

In the past year, the growth of prescription drug utilization and spending has much to do with the use of GLP-1 agonists to treat diabetes and obesity, along with immunology therapy, and lipid meds, along with specialty medicines now accounting for over half of spending up from 49% in 2018

Segt a vrcukorszint szablyozsban

Novo Nordisk has launched the Medicare GLP-1 Bridge, making Wegovy available to eligible Medicare beneficiaries for $50 a month through the end of 2027, giving millions of older adults with obesity a structured pathway to the FDA-approved weight management drug.